A JAK of All Trades: The Use of JAKi in a Patient With Erythema Annulare Centrifugum

Erythema annulare centrifugum (EAC) is a type of figurate erythema with an unclear etiology, often thought to be a delayed hypersensitivity reaction to various antigens. While many cases resolve spontaneously, chronic and refractory presentations can be challenging to manage. We report a case of EAC unresponsive to traditional treatments but demonstrating rapid improvement with upadacitinib, a selective Janus kinase (JAK) inhibitor. This case highlights a novel use for JAK inhibitors in treating EAC.